Narrow your search

Library

KBR (5)

UCLouvain (3)

UAntwerpen (1)

UGent (1)

ULB (1)

ULiège (1)

UNamur (1)

VUB (1)


Resource type

book (11)

dissertation (1)


Language

French (10)

English (2)


Year
From To Submit

2020 (1)

2015 (1)

2001 (2)

1990 (1)

1989 (1)

More...
Listing 1 - 10 of 12 << page
of 2
>>
Sort by

Book
La bilharziose uro-génitale : rapport présenté à  la session, Paris, 9-13 Octobre 1977
Author:
Year: 1977 Publisher: Paris Masson

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Dissertation
Implémentation d'une procédure de vérification de l'équivalence des échecs
Authors: ---
Year: 1990 Publisher: [S.l.]: [chez l'auteur],

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Book
A propos du traitement des fistules vésico-vaginales ; tactique opératoire dans les vastes brèches vésicales, avec sphincter conserve, consécutives principalement au traitement mixte, radium-chirurgie, des épithéliomas du col utérin. La cystoplastie ¸par rabattement¸ du détrusor et l'épiplooplastie vésicale
Author:
Year: 1963 Publisher: Paris A. G. E. M. P

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords

Dictionnaire d'urologie et de néphrologie : français-anglais
Authors: --- ---
ISBN: 285319289X 9782853192897 Year: 2001 Publisher: Paris : Conseil International de la Langue Française (CILF),


Book
Gestion optimale de l'énergie dans l'industrie
Authors: --- ---
Year: 1989 Publisher: Paris TI

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
Séminaires d'uro-néphrologie Pitié-Salpêtrière : quatorzième série 1988
Authors: --- ---
ISBN: 222581399X Year: 1988 Publisher: Paris Barcelone Mexico Masson

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Book
Séminaires d'uro-néphrologie Pitié-Salpêtrière : douzième série 1986
Authors: --- ---
ISBN: 2225808317 Year: 1986 Publisher: Paris Barcelone Mexico Masson

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Book
Séminaires d'uro-néphrologie Pitié-Salpêtrière : treizième série 1987
Authors: --- ---
ISBN: 2225810990 Year: 1987 Publisher: Paris Barcelone Mexico Masson

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Book
Gazyva, un traitement prometteur pour les patients atteints d'une leucémie lymphoïde chronique ?
Authors: --- ---
Year: 2015 Publisher: Bruxelles: UCL. Faculté de pharmacie et des sciences biomédicales,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Chronic lymphocytic leukemia is the most common leukemia in adults. Despite its status as a rare disease, the development of new treatments is booming. For about twenty years now, monoclonal antibodies have revolutionized the treatment of cancers. The first monoclonal antibody discovered was the rituximab, this one targeting the CD20 antigen found on the membrane of B Lymphocytes. They are a lot of them in chronic lymphocytic leukemia; it will prove that the treatment was effective in this disease. Following this discovery, the researchers go beyond and try to obtain more effective monoclonal antibodies. What treatments are available for patients with chronic lymphocytic leukemia? What are the benefits of targeted therapy? How did we come to monoclonal antibodies? And especially what improvements brings Gazyva ? La leucémie lymphoïde chronique est la leucémie la plus fréquente chez les adultes. Malgré son statut de maladie rare, le développement de nouveaux traitements est en pleine expansion. Depuis une vingtaine d'années, les anticorps monoclonaux ont révolutionné la thérapeutique des cancers. Le premier anticorps monoclonal découvert fut le rituximab, celui-ci ciblait l'antigène CD20 présent sur la membrane des lymphocytes B. Ces derniers étant très nombreux dans la leucémie lymphoïde chronique, il s'avèrera que le traitement était efficace dans cette maladie. Suite à cette découverte, les chercheurs se dépassent et tentent d'obtenir des anticorps monoclonaux de plus en plus efficace. Quels sont les traitements disponibles pour les patients atteints de leucémie lymphoïde chronique ? Quelles sont les avantages d'une thérapie ciblée ? Comment en sommes-nous arrivés aux anticorps monoclonaux ? Et surtout quelles améliorations apporte le Gazyva® ?


Book
In vitro platelet production from human peripheral blood CD34+ cells
Authors: --- ---
Year: 2001 Publisher: Bruxelles: UCL,

Loading...
Export citation

Choose an application

Bookmark

Abstract

In clinical practice, the use of platelet transfusion has increases progressively. A common complication is platelet alloimmunization, a major cause for refractoriness to repeated platelet transfusions. Therefore several attempts mere made to produce autologous platelets in-vitro to prevent this complication.
In this study, we were able to produce platelets in-vitro from cultured human peripheral blood stem cells (DC34+) in liquid culture medium that promotes megakaryocytopoiesis and thrombocytopoiesis.
Cells in culture did show a high proliferative capacity throughout the culture days, with megakaryocytic proliferation and differenciation, in the presence of growth factors that stimulate megakaryocytopoiesis and thrombocytopoiesis (rh-TPO, rh-IL-3, rh-IL-6, and rh-IL-11).
The megakaryocytic cells were identified by flow cytometry as CD61+ cells with scatter properties of nucleated cells, by morphology, by immunocytochemistry. MKs were first observed in culture medium from 7 days, many of them releasing proplatelets. They reached a peak on day 14. Thereafter cells disappeared from the culture medium. Most of the MKs did not show a ploidy of more than 4N by our measurement methodology and only a very few proportion of them reached 8N.
Culture-derived were detected as CD41+ events and shared the same scatter properties of normal blood platelets in flow cytometry. Although they are successfully produced in culture, they seem to be somewhat activated since expression of P-selectin (GMP 140; CD62+) detected by flow cytometry, a finding that makes their clinical use still questionable. They appeared from day 7 and reached a peak on day 14.
In summary, we settled a technology for producing platelets in in-vitro culture. These platelets show characteristics of normal platelets; however, more experiments are required in order to improve their rate of production and to obtain a normal function

Listing 1 - 10 of 12 << page
of 2
>>
Sort by